Susquehanna International Group, LLP Biomarin Pharmaceutical Inc Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 110,123 shares of BMRN stock, worth $6.98 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

110,123

Previous 37,078 197.0%

Holding current value

$6.98 Million

Previous $3.05 Million 153.6%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $5.04 Million - $6.85 Million	73,045 Added 197.0%	110,123 $7.74 Million
Q2 2024 Aug 15, 2024	SELL	$74.43 - $92.22 $47.6 Million - $59 Million	-639,608 Reduced 94.52%	37,078 $3.05 Million
Q1 2024 May 07, 2024	BUY	$83.81 - $99.0 $35 Million - $41.3 Million	417,128 Added 160.71%	676,686 $59.1 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $4.21 Million - $5.44 Million	-55,190 Reduced 17.53%	259,558 $25 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $10.4 Million - $11.6 Million	-122,730 Reduced 28.05%	314,748 $27.8 Million
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $7.76 Million - $8.98 Million	89,563 Added 25.74%	437,478 $37.9 Million
Q1 2023 May 16, 2023	BUY	$87.74 - $117.27 $13.6 Million - $18.2 Million	155,060 Added 80.4%	347,915 $33.8 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $6.5 Million - $8.72 Million	-80,282 Reduced 29.39%	192,855 $20 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $21.7 Million - $25.6 Million	264,455 Added 3046.01%	273,137 $23.2 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $6.25 Million - $7.59 Million	-87,429 Reduced 90.97%	8,682 $720,000
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $1.8 Million - $2.24 Million	-24,194 Reduced 20.11%	96,111 $7.41 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $7.32 Million - $9.34 Million	-102,090 Reduced 45.9%	120,305 $10.6 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $7.22 Million - $8.25 Million	96,560 Added 76.74%	222,395 $17.2 Million
Q2 2021 Aug 11, 2021	SELL	$75.51 - $84.79 $22.4 Million - $25.1 Million	-296,140 Reduced 70.18%	125,835 $10.5 Million
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $4.32 Million - $5.24 Million	57,791 Added 15.87%	421,975 $31.9 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $11.5 Million - $14.3 Million	158,217 Added 76.82%	364,184 $31.9 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $3.24 Million - $5.91 Million	45,096 Added 28.03%	205,967 $15.7 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $4.13 Million - $6.44 Million	-51,873 Reduced 24.38%	160,871 $19.8 Million
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $27.3 Million - $37.1 Million	-383,070 Reduced 64.29%	212,744 $18 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $9.32 Million - $12.5 Million	144,939 Added 32.15%	595,814 $50.4 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $20.9 Million - $26.4 Million	309,777 Added 219.55%	450,875 $30.4 Million
Q2 2019 Aug 16, 2019	BUY	$80.35 - $93.9 $1.09 Million - $1.27 Million	13,534 Added 10.61%	141,098 $12.1 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $5.26 Million - $6.15 Million	-65,465 Reduced 33.91%	127,564 $10.9 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $10.6 Million - $13.8 Million	138,975 Added 257.1%	193,029 $18.2 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $11.5 Million - $13.8 Million	-148,539 Reduced 73.32%	54,054 $4.38 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $15 Million - $17.7 Million	186,042 Added 1124.05%	202,593 $18.1 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $1.33 Million - $1.57 Million	16,551	16,551 $1.54 Million

Others Institutions Holding BMRN

# of Institutions

635

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Biomarin Pharmaceutical Inc Transaction History